SGC-CBP30: Selective CREBBP/EP300 Bromodomain Inhibitor Insights

Executive Summary: SGC-CBP30 is a potent and selective small molecule inhibitor of the CREBBP and EP300 bromodomains (IC₅₀: 21 nM and 38 nM), as reported by APExBIO. These coactivators are key regulators of gene expression and chromatin accessibility. SGC-CBP30 has demonstrated efficacy in HeLa and RKO cell lines, modulating transcriptional activity and impacting p53 signaling. Recent studies have linked CREBBP/EP300 function to super-enhancer hijacking and TGF-β/SMAD3 signaling in early-stage lung adenocarcinoma, highlighting translational applications (Zhang et al., 2022). The compound's unique selectivity and robust performance underpin its value in epigenetics and cancer biology research.

Biological Rationale

CREBBP (CREB-binding protein) and EP300 (E1A binding protein p300) are transcriptional coactivators with intrinsic histone acetyltransferase activity. They regulate chromatin structure by acetylating histone and non-histone proteins, enabling gene activation. Bromodomains within these proteins recognize acetylated lysine residues, targeting CREBBP/EP300 to specific genomic loci. Disruption of this recognition event is implicated in oncogenesis, particularly through altered enhancer and super-enhancer dynamics (Zhang et al., 2022).

Mechanism of Action of SGC-CBP30

SGC-CBP30 is a synthetic small molecule designed to inhibit the bromodomains of CREBBP and EP300 selectively. By competitively binding to the acetyl-lysine recognition pocket, SGC-CBP30 blocks the recruitment of these coactivators to chromatin, thereby attenuating downstream gene transcription. The reported IC₅₀ values are 21 nM for CREBBP and 38 nM for EP300, confirming nanomolar potency (product information). The inhibitor does not substantially affect other bromodomain-containing proteins at these concentrations, minimizing off-target effects. This selectivity enables researchers to dissect the roles of CREBBP/EP300 in epigenetic regulation and super-enhancer function.

Evidence & Benchmarks

• SGC-CBP30 exhibits IC₅₀ values of 21 nM (CREBBP) and 38 nM (EP300) in biochemical assays (product page).
• In HeLa and RKO cell lines, SGC-CBP30 reduces FRAP recovery times and inhibits doxorubicin-induced p53 activity in a dose-dependent manner (APExBIO).
• Super-enhancer hijacking of lncRNA LINC01977 in lung adenocarcinoma requires CREBBP/EP300 coactivator function, as shown by ChIP-seq and in vitro assays (Zhang et al., 2022).
• SGC-CBP30 enables the study of CREBBP/EP300-dependent transcriptional regulation linked to TGF-β/SMAD3 signaling pathways in cancer models (Chempaign.net).
• Optimized solubility: ≥20.05 mg/mL in DMSO, ≥25.7 mg/mL in ethanol (with ultrasonic assistance), and ≥4.67 mg/mL in water (with ultrasonic assistance) (APExBIO).

Applications, Limits & Misconceptions

SGC-CBP30 has been utilized in chromatin biology, transcriptional regulation, and cancer biology research. Its selectivity allows for specific interrogation of CREBBP/EP300 function in enhancer and super-enhancer contexts, including the study of oncogenic lncRNA regulation in lung adenocarcinoma. The compound is particularly valuable for exploring TGF-β/SMAD3 signaling axis and its role in tumor progression (Zhang et al., 2022).

For more on how SGC-CBP30 empowers translational epigenetics, see this thought-leadership article, which contextualizes the inhibitor's impact on experimental design and clinical research, updating prior syntheses.

Common Pitfalls or Misconceptions

• SGC-CBP30 does not inhibit bromodomains outside the CREBBP/EP300 family at recommended concentrations; off-target effects should not be assumed (see analysis).
• It is not a pan-bromodomain inhibitor; efficacy in BET bromodomain contexts (e.g., BRD4) is minimal.
• Long-term storage of SGC-CBP30 solutions at room temperature leads to degradation; solid-form storage at 4°C is recommended (APExBIO).
• In vivo efficacy data for SGC-CBP30 in animal models of lung adenocarcinoma remains limited; most evidence is from in vitro or ex vivo systems (Zhang et al., 2022).
• SGC-CBP30 is not designed as a therapeutic agent; its primary use is as a research probe.

Workflow Integration & Parameters

• Stock solution preparation: Dissolve SGC-CBP30 at ≥20.05 mg/mL in DMSO, ≥25.7 mg/mL in ethanol (with ultrasound), or ≥4.67 mg/mL in water (with ultrasound); filter sterilize as needed.
• Storage: Store solid SGC-CBP30 at 4°C for optimal stability; stock solutions can be stored below -20°C for several months, but repeated freeze-thaw cycles and long-term storage in solution should be avoided.
• Cellular assay concentration: Typical working concentrations range from 0.1 to 10 μM, with dose-dependent effects observed in HeLa and RKO cell lines (APExBIO).
• Protocol for transcriptional inhibition: Treat cells with SGC-CBP30 for 1–24 hours prior to endpoint analysis; adjust exposure time based on cell type and readout.
• Controls: Include vehicle-only and unrelated bromodomain inhibitor controls to verify specificity (see workflow recommendations).

Conclusion & Outlook

SGC-CBP30, as distributed by APExBIO, is a robust, selective inhibitor of CREBBP/EP300 bromodomains. Its chemical and biological specificity enable detailed study of epigenetic regulation, including super-enhancer hijacking mechanisms linked to malignancy in early-stage lung adenocarcinoma (Zhang et al., 2022). While in vivo data remain emergent, SGC-CBP30 provides a reliable foundation for experiments addressing transcriptional coactivator inhibition, epigenetic vulnerabilities, and disease-relevant signaling pathways. For further reading on super-enhancer mechanisms in LUAD, see this article, which SGC-CBP30-focused studies now clarify by directly probing the CREBBP/EP300 axis.